Click image to view it in full size

The diabetes industry offers significant opportunities for growth, given the rising prevalence of this disease condition. However the devices space comprising self-monitoring of blood glucose (SMBG, or glucometer), continuous glucose monitors (CGMs), insulin pens, and insulin pumps are facing unprecedented threats and challenges, some of which are definitely opportunities in disguise.

Each diabetes device manufacturer planning their short-term (1-3 year) and long-term (5-7 year) strategies must look in to the broader diabetes market trends, to see what their peers within the same and adjacent device category are aiming for, how the pharmaceutical industry is impacting the diabetes space, how emerging disease management approaches and trends of virtual care are impacting the space. One of the trends impacting the SMBG and CGM players is that of non-invasive monitoring tech. The space remains an emerging approach for almost a decade now, but with little success for even those who managed some regulatory approvals, but it could impact the industry in the 5-7 year timeframe. Beyond the competitive trends, it is crucial to also understand regional differences and how to target the huge emerging market potential, which remains an acknowledged, but an untapped opportunity.